Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Meningococcal Polysaccharide Diphtheria Toxoid Conjugate: Menactra · 2 trials · 2 indications
Immunogenicity tests were performed at 19 months of age in Menactra Vaccine Group after Menactra® vaccination and performed at 13 months and 19 months of age in the Menjugate Vaccine Group after Menjugate® vaccination
Immunogenicity tests were performed at 19 months of age in Menactra Vaccine Group after Menactra® vaccination and performed at 13 months and 19 months of age in the Menjugate Vaccine Group after Menjugate® vaccination
Meningococcal antibodies against serogroups A, C, Y, and W-135 were assessed by serum bactericidal assay using human complement (SBA-HC)
| Arm | Type | Description |
|---|---|---|
| Menactra® Vaccine Group | EXPERIMENTAL | Meningococcal vaccine naive participants will receive Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate vaccine (Menactra®) at 12 months of age and at 18 months of age concomitantly with routine vaccines administered as per provincial schedule |
| Menjugate® Vaccine Group | ACTIVE_COMPARATOR | Meningococcal vaccine naive participants will receive MenC vaccine (Menjugate) given concomitantly at 12 months of age with routine vaccines administered as per provincial schedule. |
| Meningococcal vaccine Group | EXPERIMENTAL | Participants must have received Menactra vaccine 4 to 6 years prior to enrollment |
| Name | Type | Description |
|---|---|---|
| Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate: Menactra® | BIOLOGICAL | 0.5 mL, Intramuscular |
| Meningococcal Group C Conjugate vaccine: MenC | BIOLOGICAL | 0.5 mL, Intramuscular |
Inclusion Criteria: * Aged 12 months (365 to 400 days) on the day of inclusion * Born at full term of pregnancy (≥ 37 weeks) and with a birth weight ≥ 2.5 kg * Informed consent form has been signed and dated by the parent(s) or other legally authorized representative * Subject and parent/legal repr...
Menactra is a vaccine used to prevent meningitis and meningococcal infection caused by meningococcal groups A, C, Y and W-135. It is a meningococcal polysaccharide diphtheria toxoid conjugate vaccine developed by Sanofi. Clinical studies have evaluated it in healthy volunteers, including adults and children, for protection against these meningococcal serogroups.
Menactra is made by Sanofi, which trades under the ticker SNY. Sanofi is the developer of this meningococcal polysaccharide diphtheria toxoid conjugate vaccine.
Menactra has been studied in Phase 3 clinical development. Two completed trials are registered, one Phase 2 and one Phase 3, with a combined enrollment of 957 participants. The Phase 3 trial evaluated two doses of Menactra or one dose of a monovalent meningococcal group C vaccine alongside routine immunizations.
Menactra has been evaluated in two completed clinical trials: NCT01442675, a Phase 2 study of a single dose of Menactra vaccine 4 to 6 years after a prior Menactra dose, and NCT01359449, a Phase 3 study of two doses of Menactra or one dose of monovalent meningococcal group C vaccine with routine immunizations.